Home/Indications/Oncology/Hepatocellular Carcinoma

Hepatocellular Carcinoma

Oncology 10 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Hepatocellular Carcinoma has 10 FDA-approved novel treatments, led by Bristol-Myers Squibb, with 626 active industry clinical trials across 33 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Hepatocellular Carcinoma Market Leaders

Companies with the most FDA-approved novel Hepatocellular Carcinoma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

TACE+Camrelizumab+Apatinib mesylate

Jiangsu HengRui Medicine Co., Ltd.

Estimated · aging NCT05320692

Q3 2026

Camrelizumab

Jiangsu HengRui Medicine Co., Ltd.

Estimated · fresh NCT04639180

Q4 2026

AK105 Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Estimated · stale NCT04344158

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Hepatocellular Carcinoma Treatments by Mechanism

Top 10 mechanisms across 34 industry trials with a known mechanism of action.

See full pipeline →

Programmed Death Receptor-1 Blocking Antibody

14 trials 7 active 4 sponsors

Programmed Death Ligand-1 Blocker

7 trials 7 active 1 sponsor

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

4 trials 2 active 2 sponsors

Vascular Endothelial Growth Factor Inhibitor

2 trials 1 active 2 sponsors

DNA

1 trials 1 active 1 sponsor

Vascular Endothelial Growth Factor Receptor 2 Antagonist

2 trials 1 sponsor

GM-CSF

1 trials 1 sponsor

Androgen Receptor Inhibitor

1 trials 1 sponsor

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Hepatocellular Carcinoma Clinical Pipeline by Phase

420 industry-sponsored trials across 241 sponsors

View full landscape →

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Guerbet	Xenetix-CT perfusion imaging	—	COMPLETED	2014-10	NCT01639703
Bayer	Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment	—	COMPLETED	2013-03	NCT01098760
Bukwang Pharmaceutical	clevudine, Adefovir	—	COMPLETED	2013-01	NCT01263002
Guerbet	Gadoterate meglumine	—	TERMINATED	2015-10-12	NCT01806740

Showing 70 of 70 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068	—	RECRUITING	2026-09	NCT06618664
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2027-12-31	NCT07490262
Polaris Group	ADI-PEG20	—	RECRUITING	2028-09	NCT05317819
Guangzhou Virotech Pharmaceutical Co., Ltd.	VRT106	—	RECRUITING	2028-12-31	NCT07589244
AstraZeneca	Tremelimumab	—	RECRUITING	2029-03-16	NCT06921785
Zhejiang Raygene Pharmaceuticals Co., Ltd	tirapazamine	—	RECRUITING	2029-04-01	NCT06844357
AbbVie	Livmoniplimab	—	RECRUITING	2030-09	NCT06109272
Can-Fite BioPharma	Namodenoson	—	RECRUITING	2026-02	NCT05201404
Akeso	AK104	—	RECRUITING	2026-01-28	NCT05489289
Akeso	AK104	—	RECRUITING	2025-10-25	NCT06371157
Beijing Shenogen Biomedical Co., Ltd	Icaritin	—	RECRUITING	2025-08-30	NCT05594927
Shandong New Time Pharmaceutical Co., LTD	Rulonilimab+Lenvatinib	—	RECRUITING	2025-08-01	NCT05408221
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Anlotinib hydrochloride capsules, Penpulimab injection	—	RECRUITING	2024-08	NCT05862337
Jiangsu HengRui Medicine Co., Ltd.	TACE+Camrelizumab+Apatinib mesylate	—	ACTIVE NOT RECRUITING	2026-07-30	NCT05320692
Jiangsu HengRui Medicine Co., Ltd.	Camrelizumab	—	ACTIVE NOT RECRUITING	2026-07-31	NCT04639180
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-09-30	NCT05557838
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	AK105 Injection	—	ACTIVE NOT RECRUITING	2026-12	NCT04344158
Chengdu New Radiomedicine Technology Co. LTD.	NRT6003 Injection	—	ACTIVE NOT RECRUITING	2027-10	NCT06900543
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2029-02-01	NCT04712643
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2026-07-09	NCT04039607
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2026-06-30	NCT04770896
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-05-29	NCT03847428
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-03-30	NCT05883644
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2026-02-27	NCT03383458
AstraZeneca	Tremelimumab	—	ACTIVE NOT RECRUITING	2026-02-23	NCT05301842
Boston Scientific Corporation	—	—	ACTIVE NOT RECRUITING	2026-02-13	NCT05016245
CStone Pharmaceuticals	Nofazinlimab (CS1003)+Lenvatinib	—	ACTIVE NOT RECRUITING	2025-06-18	NCT04194775
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2025-05-08	NCT05904886
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2023-09-11	NCT03778957
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2021-11-30	NCT03755791
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2021-08-27	NCT03298451
InnoBM Pharmaceuticals Co., Ltd.	—	—	NOT YET RECRUITING	2027-06	NCT06779461
Shanghai Henlius Biotech	HLX13	—	NOT YET RECRUITING	2027-06-06	NCT06841185
Changchun GeneScience Pharmaceutical Co., Ltd.	Nanocrystalline Megestrol Acetate	—	NOT YET RECRUITING	2027-06-30	NCT07356037
Qilu Pharmaceutical Co., Ltd.	QL1706	—	NOT YET RECRUITING	2027-09-01	NCT05976568
Tempest Therapeutics	TPST-1120	—	NOT YET RECRUITING	2028-12	NCT06680258
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH006	—	NOT YET RECRUITING	2030-03-01	NCT07392866
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	NOT YET RECRUITING	2030-05-31	NCT07620574
Innovent Biologics (Suzhou) Co. Ltd.	IBI310	—	COMPLETED	2025-12-31	NCT04720716
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2025-03-20	NCT03867084
BeiGene	Tislelizumab	—	COMPLETED	2022-07-11	NCT03412773
SillaJen, Inc.	Pexastimogene Devacirepvec (Pexa Vec)	—	COMPLETED	2020-07	NCT02562755
Imunon	ThermoDox	—	COMPLETED	2020-04-27	NCT02112656
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Donafenib	—	COMPLETED	2019-11-27	NCT02645981
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-05-30	NCT02576509
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-01-02	NCT02702401
Eli Lilly	Ramucirumab	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	COMPLETED	2018-03-15	NCT02435433
Exelixis	Cabozantinib tablets	—	COMPLETED	2017-10-16	NCT01908426
Kyowa Kirin Co., Ltd.	ARQ197	—	COMPLETED	2017-08	NCT02029157
Daiichi Sankyo	Tivantinib	—	COMPLETED	2017-03-28	NCT01755767
Eisai Limited	Lenvatinib	—	COMPLETED	2016-11-13	NCT01761266
Biotest Pharmaceuticals Corporation	Civacir® 10%	—	COMPLETED	2016-02	NCT01804829
Polaris Group	ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)	—	COMPLETED	2015-07	NCT01287585
Eli Lilly	Ramucirumab DP (IMC-1121B)	—	COMPLETED	2014-03	NCT01140347
Imunon	ThermoDox	—	COMPLETED	2013-01	NCT00617981
GC Cell Corporation	Immuncell-LC	—	COMPLETED	2012-11	NCT00699816
Bristol-Myers Squibb	Brivanib	—	COMPLETED	2012-09-28	NCT00908752
Bristol-Myers Squibb	Brivanib	—	COMPLETED	2011-11-15	NCT00825955
Beijing Shenogen Biomedical Co., Ltd	Icaritin	—	TERMINATED	2022-02-08	NCT03236649
Jiangsu HengRui Medicine Co., Ltd.	camrelizumab；Rivoceranib	—	TERMINATED	2021-12-29	NCT04985136
Merit Medical Systems, Inc.	—	—	TERMINATED	2021-02	NCT01387932
Boston Scientific Corporation	Sorafenib	—	TERMINATED	2017-06-05	NCT02460991
Boston Scientific Corporation	Sorafenib	—	TERMINATED	2017-05-23	NCT01887717
Cellxpert Biotechnology Corp.	PI-88	—	TERMINATED	2014-07	NCT01402908
Taiho Pharmaceutical Co., Ltd.	Orantinib (TSU-68)	—	TERMINATED	2014-06	NCT01465464
Abbott	ABT-869	—	TERMINATED	2012-07	NCT01009593
Mirror Biologics, Inc.	AlloStim® immunotherapy	—	SUSPENDED	2026-11-01	NCT05033522
BeiGene	Sitravatinib	—	WITHDRAWN	2027-04-30	NCT05564338
Shanghai Henlius Biotech	HLX10	—	WITHDRAWN	2023-10-15	NCT04465734
Accuray Incorporated	—	—	WITHDRAWN	2014-02	NCT01318200

Showing 100 of 215 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	ZG005 for Injection	—	RECRUITING	2026-09	NCT06558227
AstraZeneca	Volrustomig	—	RECRUITING	2026-10-27	NCT05775159
3D Medicines (Sichuan) Co., Ltd.	Lenvatinib + Envafolimab	—	RECRUITING	2026-12	NCT05024214
Zhejiang Haichang Biotech Co., Ltd.	WGI-0301 at MTD/RP2D dose IV infusion, QW	—	RECRUITING	2026-12	NCT06309485
OriCell Therapeutics Co., Ltd.	Ori-C101	—	RECRUITING	2026-12	NCT05652920
Teclison Ltd.	Nivolumab Injectable Product	—	RECRUITING	2026-12-30	NCT03259867
TaiRx, Inc.	Nivolumab Injection [Opdivo]	—	RECRUITING	2026-12-31	NCT05257590
Lukas Biomedical Inc.	ATL administration	—	RECRUITING	2026-12-31	NCT05304481
Tvardi Therapeutics, Incorporated	TTI-101	—	RECRUITING	2027-02-01	NCT05440708
Beijing Biotech	EB-G3B7-NK dual-target CAR-NK cells	—	RECRUITING	2027-03-14	NCT07500220
Riboscience, LLC.	RBS2418	—	RECRUITING	2027-04	NCT07175441
Parabilis Medicines, Inc.	FOG-001	—	RECRUITING	2027-04-01	NCT05919264
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2027-05	NCT06986785
Akeso	TT-00420 (tinengotinib)	—	RECRUITING	2027-05-10	NCT07052253
Febico Biomedical Corp.	FB-1603	—	RECRUITING	2027-06-07	NCT06478719
Abbisko Therapeutics Co, Ltd	ABSK-011+BSC	—	RECRUITING	2027-06-30	NCT07327034
GV20 Therapeutics	GV20-0251	—	RECRUITING	2027-07-16	NCT07070518
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2027-07-30	NCT06096779
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2027-07-30	NCT04524871
Zhejiang Hisun Pharmaceutical Co. Ltd.	AST-3424	—	RECRUITING	2027-10-01	NCT07310173
Pfizer	PF-08634404	—	RECRUITING	2027-10-18	NCT07227012
Replimune, Inc.	RP2	—	RECRUITING	2027-12-01	NCT05733598
GrandPharma (China) Co., Ltd.	Yttrium [90Y] Microsphere Injection	—	RECRUITING	2027-12-30	NCT07334483
TaiRx, Inc.	—	—	RECRUITING	2027-12-31	NCT07521852
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
Eureka Therapeutics Inc.	ECT204 T cells	—	RECRUITING	2027-12-31	NCT04864054
AstraZeneca	AZD9793 Intravenous (IV) monotherapy	—	RECRUITING	2028-02-25	NCT06795022
Teclison Ltd.	Tirapazamine	—	RECRUITING	2028-03-31	NCT02174549
Huahui Health	Will receive HH-009 injection 20 mg/kg, Q3W	—	RECRUITING	2028-10-30	NCT07547553
Newish Technology (Beijing) Co., Ltd.	NWRD06 administered by electroporation	—	RECRUITING	2028-12-31	NCT07324304
CatalYm GmbH	Visugromab RDE (recommended dose for expansion)	—	RECRUITING	2029-09	NCT07219459
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2029-10-15	NCT07291076
Shanghai AbelZeta Ltd.	Armored and GPC3-targeted autologous CAR T-cell	—	RECRUITING	2030-04-30	NCT06590246
RayzeBio, Inc.	RYZ801	—	RECRUITING	2030-06	NCT06726161
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Adebrelimab	—	RECRUITING	2026-06-30	NCT05444088
Akeso	AK112	—	RECRUITING	2026-06	NCT06530251
Iterion Therapeutics	Tegavivint	—	RECRUITING	2026-05	NCT05797805
Eureka Therapeutics Inc.	ET140203 T Cells	—	RECRUITING	2026-01-31	NCT04634357
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Virogin Biotech Canada Ltd	VG161	—	RECRUITING	2025-10-01	NCT05223816
SCG Cell Therapy Pte. Ltd.	SCG101	—	RECRUITING	2025-09	NCT05417932
CAS Lamvac Biotech Co., Ltd.	Blood-stage infection of P.vivax	—	RECRUITING	2023-06-30	NCT03474822
GSK	Cobolimab	—	ACTIVE NOT RECRUITING	2026-10-13	NCT06521567
AbbVie	Budigalimab	—	ACTIVE NOT RECRUITING	2026-11	NCT05822752
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-11-30	NCT07081633
Boston Scientific Corporation	Durvalumab (Imfinzi) immunotherapy	—	ACTIVE NOT RECRUITING	2027-06	NCT05063565
Indaptus Therapeutics, Inc	Decoy20	—	ACTIVE NOT RECRUITING	2027-06-30	NCT05651022
BioInvent International AB	BI-1910	—	ACTIVE NOT RECRUITING	2027-07-14	NCT06205706
Coherus Oncology, Inc.	Casdozokitug	—	ACTIVE NOT RECRUITING	2027-09	NCT06679985
AstraZeneca	AZD5851	—	ACTIVE NOT RECRUITING	2027-12-13	NCT06084884
ImmunityBio, Inc.	N-803 + Pembrolizumab	—	ACTIVE NOT RECRUITING	2029-08-31	NCT03228667
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-07-01	NCT06040099
Biotheus Inc.	PM8002	—	ACTIVE NOT RECRUITING	2026-06	NCT05864105
Ascentawits Pharmaceuticals, Ltd	AST-3424	—	ACTIVE NOT RECRUITING	2025-11-30	NCT06239155
Sotio Biotech Inc.	CAR-GPC3 T Cells	—	ACTIVE NOT RECRUITING	2025-10-24	NCT05120271
Salubris Biotherapeutics Inc	JK08	—	ACTIVE NOT RECRUITING	2025-10-17	NCT05620134
Regeneron	cemiplimab	—	ACTIVE NOT RECRUITING	2025-03-31	NCT03916627
Geneos Therapeutics	GNOS-PV02	—	ACTIVE NOT RECRUITING	2024-11-29	NCT04251117
ImmunoVaccine Technologies, Inc. (IMV Inc.)	Cyclophosphamide	DNA	ACTIVE NOT RECRUITING	2023-12-31	NCT03836352
Akeso	AK104	—	ACTIVE NOT RECRUITING	2023-08-15	NCT05319431
MedImmune LLC	Tremelimumab	—	ACTIVE NOT RECRUITING	2020-11-06	NCT02519348
Tasly Biopharmaceuticals Co., Ltd.	B1962	—	NOT YET RECRUITING	2026-08	NCT06724263
Biotheus Inc.	PM8002	—	NOT YET RECRUITING	2026-10	NCT06584071
Beijing Gene Key Life Technology Co., Ltd	GKL-006	—	NOT YET RECRUITING	2026-10-31	NCT07209813
Akeso	AK104+lenvatinib	—	NOT YET RECRUITING	2026-11-30	NCT06984718
Lion TCR Pte. Ltd.	LioCyx-M	—	NOT YET RECRUITING	2026-12	NCT05195294
Second Life Therapeutics	SL-28	—	NOT YET RECRUITING	2027-01-01	NCT07341737
Twinpig Biolab, Inc.	TB511	—	NOT YET RECRUITING	2027-03	NCT06400160
Broadenbio Ltd., Co.	BB102	—	NOT YET RECRUITING	2027-06	NCT07239986
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	Autologous immune Cells	—	NOT YET RECRUITING	2027-06-30	NCT07260058
Lepu Biopharma Co., Ltd.	MRG006A	—	NOT YET RECRUITING	2028-04	NCT07479485
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	HA131	—	NOT YET RECRUITING	2028-06-26	NCT07282509
Zhejiang Haichang Biotech Co., Ltd.	WGI-0301	—	NOT YET RECRUITING	2028-09	NCT07540832
Sirtex Medical	—	—	NOT YET RECRUITING	2029-10	NCT07663487
VM Discovery, Inc.	VMD-102	—	NOT YET RECRUITING	2031-05	NCT07636785
CNBG-Virogin Biotech (Shanghai) Ltd.	Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))	—	NOT YET RECRUITING	2025-12-30	NCT06124001
Biocity Biopharmaceutics Co., Ltd.	BC3402 injection	—	NOT YET RECRUITING	2024-08	NCT06111326
Merck	Pembrolizumab/Vibostolimab Co-Formulation	—	COMPLETED	2025-08-05	NCT05007106
Merck	Pembrolizumab/Quavonlimab	—	COMPLETED	2025-07-29	NCT04740307
Coherus Oncology, Inc.	SRF388	—	COMPLETED	2025-06-30	NCT05359861
SOFIE	[18F]FAPI-74 PET/CT	—	COMPLETED	2025-06-30	NCT05641896
Akeso	AK112	—	COMPLETED	2025-04-30	NCT05432492
Mina Alpha Limited	MTL-CEBPA	—	COMPLETED	2025-01-25	NCT04710641
Medivir	MIV-818 (fostroxacitabine bralpamide) + pembrolizumab	—	COMPLETED	2025-01-07	NCT03781934
Jiangsu HengRui Medicine Co., Ltd.	Camrelizumab、Rivoceranib	—	COMPLETED	2024-11-15	NCT05367687
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-11-12	NCT01658878
Yiviva Inc.	Sorafenib+YIV-906	—	COMPLETED	2024-03-22	NCT04000737
BeiGene	Ociperlimab	—	COMPLETED	2024-02-01	NCT04948697
Akeso	AK104	—	COMPLETED	2023-11-20	NCT04444167
Vaxcell Bio, Co., Ltd.	Vax-NK/HCC	—	COMPLETED	2023-09-14	NCT05040438
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2023-08-31	NCT04567615
Sanofi	THOR-707	—	COMPLETED	2023-07-26	NCT05104567
Intensity Therapeutics, Inc.	INT230-6	—	COMPLETED	2023-02-22	NCT03058289
BeiGene	Lenvatinib	—	COMPLETED	2022-12-01	NCT04401800
Akeso	AK104 lenvatinib	—	COMPLETED	2022-08-02	NCT04728321
Akeso	AK105	—	COMPLETED	2022-06-01	NCT04172571
Suzhou Kintor Pharmaceutical Inc,	GT90001 and Nivolumab	—	COMPLETED	2022-05-26	NCT03893695
Bayer	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-05-05	NCT04696055
Amgen	Talimogene Laherparepvec	GM-CSF	COMPLETED	2022-02-14	NCT02509507
Klus Pharma Inc.	A166	—	COMPLETED	2022-01-12	NCT03602079

Showing 100 of 131 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
Shanghai JMT-Bio Inc.	JMT106 Injection	—	RECRUITING	2026-11-05	NCT07275073
Shanghai Henlius Biotech	HLX13	—	RECRUITING	2026-12	NCT07176650
Betta Pharmaceuticals Co., Ltd.	BPI-371153	—	RECRUITING	2026-12	NCT05341557
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH009	—	RECRUITING	2026-12-30	NCT07390838
CARsgen Therapeutics Co., Ltd.	CT011 CAR-GPC3 T Cells Injection	—	RECRUITING	2026-12-31	NCT06560827
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Etnova Therapeutics Corp.	ETN101	—	RECRUITING	2027-03-07	NCT06326502
Qurgen Inc.	SON-DP	—	RECRUITING	2027-04	NCT06873659
Chiome Bioscience Inc.	CBA-1205 Part 1	—	RECRUITING	2027-06-30	NCT06636435
Zymeworks BC Inc.	ZW251	—	RECRUITING	2027-09	NCT07164313
Alnylam Pharmaceuticals	ALN-BCAT	—	RECRUITING	2027-09-30	NCT06600321
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-2524 Injection	—	RECRUITING	2027-10	NCT07478302
AbbVie	Livmoniplimab	—	RECRUITING	2027-10	NCT06487559
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0610 for Injection	—	RECRUITING	2027-12	NCT07348211
Lion TCR Pte. Ltd.	LioCyx-M, HBV antigen-specific TCR-redirected T cells	—	RECRUITING	2027-12-01	NCT06961617
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Abbisko Therapeutics Co, Ltd	ABSK-011	—	RECRUITING	2027-12-31	NCT04906434
Myeloid Therapeutics	MT-303	—	RECRUITING	2027-12-31	NCT06478693
LaunXP Biomedical Co., Ltd.	LXP1788 is administered intravenously via Port-A	—	RECRUITING	2027-12-31	NCT06883539
Tyra Biosciences, Inc	TYRA-430	—	RECRUITING	2028-01	NCT06915753
Seagen, a wholly owned subsidiary of Pfizer	PF-08046054	—	RECRUITING	2028-01-05	NCT05208762
Compass Therapeutics	CTX-10726	—	RECRUITING	2028-04-01	NCT07419841
Guangzhou FineImmune Biotechnology Co., LTD.	Super CAR-T	—	RECRUITING	2028-04-30	NCT07493044
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
BeOne Medicines	BGB-B2033	—	RECRUITING	2028-05-30	NCT06427941
Roche	Enzelkitug	—	RECRUITING	2028-07-31	NCT05581004
Bayer	BAY 3547926	—	RECRUITING	2029-07-31	NCT06764316
Shenzhen Xinhe Biomedical	XH001 Injection	—	RECRUITING	2029-10-30	NCT07594964
SEED Therapeutics, Inc.	ST-01156	—	RECRUITING	2029-12-31	NCT07197554
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Lion TCR Pte. Ltd.	mRNA HBV/TCR T-cells	—	RECRUITING	2026-07-01	NCT04745403
SAPU NANO (US) LLC	Sapu003	—	RECRUITING	2026-06	NCT07369505
SCG Cell Therapy Pte. Ltd.	SCG101	—	RECRUITING	2025-12-31	NCT06617000
Lee's Pharmaceutical Limited	AU409	—	RECRUITING	2025-12-28	NCT06374485
TORL Biotherapeutics, LLC	TORL-4-500	—	RECRUITING	2025-10-31	NCT06005740
Binhui Biopharmaceutical Co., Ltd.	OH2 injection	—	RECRUITING	2025-08	NCT05698459
BioEclipse Therapeutics	CRX100 suspension for infusion	—	RECRUITING	2025-08	NCT04282044
CNBG-Virogin Biotech (Shanghai) Ltd.	Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))	—	RECRUITING	2022-03-21	NCT04806464
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH006	—	ACTIVE NOT RECRUITING	2026-12-30	NCT07362264
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
AbbVie	ABBV-400	—	ACTIVE NOT RECRUITING	2026-07	NCT06084481
Chugai Pharmaceutical	ERY974	—	ACTIVE NOT RECRUITING	2025-12-31	NCT05022927
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
AccSalus Biosciences, Inc.	ACC-1898	—	NOT YET RECRUITING	2027-06	NCT07252661
Huahui Health	HH160	—	NOT YET RECRUITING	2028-08	NCT07623369
Captor Therapeutics S.A.	CT-01	—	NOT YET RECRUITING	2029-04-16	NCT06994572
Corregene Biotechnology Co., Ltd	CRPA1A2	—	NOT YET RECRUITING	2030-03-30	NCT07583316
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Intervention1：FXB0871	—	NOT YET RECRUITING	2030-04-23	NCT07558200
Boehringer Ingelheim	BI 765049	—	COMPLETED	2025-08-15	NCT06091930
Arbele Pty Ltd	Cabotamig (ARB202)	—	COMPLETED	2025-07-23	NCT05411133
Chengdu New Radiomedicine Technology Co. LTD.	NRT6003 Injection	—	COMPLETED	2025-06-10	NCT06310590
Coherus Oncology, Inc.	CHS-388	—	COMPLETED	2025-05-28	NCT04374877
NantBioScience, Inc.	YE-NEO-001	—	COMPLETED	2025-03-18	NCT03552718
Bayer	BAY3630942	—	COMPLETED	2025-03-10	NCT06345001
Incyte Corporation	INCB099280	—	COMPLETED	2024-08-29	NCT04242199
Innovent Biologics (Suzhou) Co. Ltd.	IBI308 200mg	—	COMPLETED	2024-06-21	NCT04401813
Xencor, Inc.	XmAb®23104	—	COMPLETED	2024-02-15	NCT03752398
Incyte Corporation	INCB106385	—	COMPLETED	2024-01-22	NCT04580485
GenVivo, Inc.	GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)	—	COMPLETED	2023-12-12	NCT04313868
Xencor, Inc.	XmAb®22841	—	COMPLETED	2023-02-16	NCT03849469
Sirnaomics	STP705	—	COMPLETED	2023-01-13	NCT04676633
Roche	RO7119929	—	COMPLETED	2023-01-09	NCT04338685
Fate Therapeutics	FT500	—	COMPLETED	2022-11-15	NCT03841110
Bayer	Copanlisib	—	COMPLETED	2022-10-13	NCT03735628
Quadriga Biosciences, Inc.	QBS10072S	—	COMPLETED	2022-09-21	NCT04430842
Tempest Therapeutics	Part 1 TPST-1120	—	COMPLETED	2022-09-07	NCT03829436
Xencor, Inc.	XmAb20717	—	COMPLETED	2022-06-01	NCT03517488
H3 Biomedicine Inc.	H3B-6527	—	COMPLETED	2022-02-23	NCT02834780
Boryung Pharmaceutical Co., Ltd	BR2008-1 (R)	—	COMPLETED	2021-11-28	NCT05068193
Lion TCR Pte. Ltd.	TCR-T	—	COMPLETED	2021-09-28	NCT02686372
Incyte Corporation	INCAGN02390	—	COMPLETED	2021-08-18	NCT03652077
Blueprint Medicines Corporation	Fisogatinib (BLU-554)	—	COMPLETED	2021-06-30	NCT02508467
CARsgen Therapeutics Co., Ltd.	CAR-GPC3 T Cells	—	COMPLETED	2021-05-28	NCT03884751
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Fate Therapeutics	FATE-NK100	—	COMPLETED	2020-05-29	NCT03319459
Novita Pharmaceuticals, Inc.	NP-G2-044	—	COMPLETED	2020-05-07	NCT03199586
Novartis	PDR001	—	COMPLETED	2020-02-27	NCT02988440
Eisai Co., Ltd.	lenvatinib	—	COMPLETED	2019-10-31	NCT03006926
Gradalis, Inc.	Vigil™	—	COMPLETED	2018-12-06	NCT01061840
Inovio Pharmaceuticals	INO-1400	—	COMPLETED	2018-11-09	NCT02960594
Sumitomo Pharma Co., Ltd.	BBI503	—	COMPLETED	2018-10	NCT02354898
Eli Lilly	Ramucirumab	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	COMPLETED	2018-03-27	NCT02572687
Sumitomo Pharma Co., Ltd.	BBI608	—	COMPLETED	2017-11	NCT02358395
Eli Lilly	LY2157299	—	COMPLETED	2017-07-19	NCT02240433
Eisai Co., Ltd.	Lenvatinib	—	COMPLETED	2017-06-28	NCT02953743
Mendus	COMBIG-DC (ilixadencel)	—	COMPLETED	2017-06-28	NCT01974661
OncoMed Pharmaceuticals, Inc.	OMP-54F28 with Sorafenib	—	COMPLETED	2017-05	NCT02069145
Polaris Group	ADI-PEG 20	—	COMPLETED	2016-02	NCT02101593
Merrimack Pharmaceuticals	MM-141	—	COMPLETED	2016-01	NCT01733004
Oncozyme Pharma Inc.	Oral Pentamidine	—	COMPLETED	2015-12	NCT02210182
AstraZeneca	AZD9150	—	COMPLETED	2015-02	NCT01839604
OrienGene Biotechnology Ltd.	Recombinant hGM-CSF Herpes Simplex Virus Injection	—	COMPLETED	2014-05	NCT01935453
Kyowa Kirin Co., Ltd.	ARQ 197	—	COMPLETED	2014-03	NCT01656265
Bristol-Myers Squibb	Brivanib	—	COMPLETED	2013-11	NCT01540461
Chugai Pharmaceutical	GC33(RO5137382)	—	COMPLETED	2013-07	NCT00976170
MedImmune LLC	MEDI-573 (1 of 3 doses)	—	COMPLETED	2013-04-09	NCT01498952
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	ARQ 197	—	COMPLETED	2011-12	NCT00802555
AstraZeneca	AZD8055	—	COMPLETED	2011-12	NCT00999882

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Hepatocellular Carcinoma

VEGF (17) RET (12) ROS1 (11) EGFR- (8) NTRK (8) FGFR (8)

Novel Hepatocellular Carcinoma Drugs by Company (New molecular entities)

6 companies have an FDA-approved novel drug for Hepatocellular Carcinoma.

Bristol-Myers Squibb 3 drugs

AstraZeneca 2 drugs

Roche 2 drugs

GUERBET 1 drug

Eli Lilly 1 drug

Merck 1 drug

Reformulations (2 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.